Palmitoyl tetrapeptide-7 (Pal-GQPR) is a lipopeptide used in cosmetic anti-aging formulations. It is designed to reduce skin inflammation by inhibiting IL-6 secretion, targeting "inflammaging" — the chronic low-grade inflammation that contributes to skin aging. It is one of the two peptides in the Matrixyl 3000 combination (alongside palmitoyl tripeptide-1). It was originally marketed as Rigin. Independent clinical data is very limited.
Category: Cosmetic Peptide. Evidence rating: F (anecdotal/unsupported).
Clinical status: Cosmetic ingredient. Minimal independent clinical data.
Palmitoyl tetrapeptide-7 reduces the secretion of interleukin-6 (IL-6) from keratinocytes and other skin cells. IL-6 is a pro-inflammatory cytokine that increases with age and UV exposure, contributing to collagen degradation and skin aging (inflammaging). By reducing IL-6 levels, Pal-GQPR aims to…
Safety considerations: Generally well tolerated in cosmetic formulations; No significant adverse effects reported; Low irritation potential.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
| US regulatory status | Cosmetic ingredient. Not FDA-regulated as a drug. |
Related peptides: Matrixyl, Matrixyl 3000, Snap-8.
It is most commonly used in combination with palmitoyl tripeptide-1 as the trademarked Matrixyl 3000 (Sederma). It can be found alone in some formulations, but the combination is far more common in the market.
Palmitoyl tetrapeptide-7 (Pal-GQPR) is a lipopeptide used in cosmetic anti-aging formulations. It is designed to reduce skin inflammation by inhibiting IL-6 secretion, targeting "inflammaging" — the chronic low-grade inflammation that contributes to skin aging. It is one of the two peptides in the Matrixyl 3000 combination (alongside palmitoyl tripeptide-1). It was originally marketed as Rigin.…
On the PeptideAtlas A–F scale, Palmitoyl Tetrapeptide-7 is rated F (Safety Concern). Safety concerns, misleading claims, or no credible basis
Cosmetic ingredient. Minimal independent clinical data.
Palmitoyl tetrapeptide-7 reduces the secretion of interleukin-6 (IL-6) from keratinocytes and other skin cells. IL-6 is a pro-inflammatory cytokine that increases with age and UV exposure, contributing to collagen degradation and skin aging (inflammaging). By reducing IL-6 levels, Pal-GQPR aims to slow inflammation-driven extracellular matrix breakdown. The palmitoyl chain enhances skin…